Back to today’s briefing

Story perspectives

Sawyer & Company Invests $4.96M in Novo Nordisk Amid Stock Decline

1/17/2025

29 6

Summary

Story summary

Sawyer & Company Inc purchased 57,691 shares of Novo Nordisk A/S for $4.96 million, ranking it 15th in their portfolio.
Novo Nordisk's stock declined after Wegovy and Ozempic were added to Medicare's price negotiation list.
Analysts hold a consensus "Buy" rating for Novo Nordisk, with a price target of $140.20.
The company boasts a market cap of $373.61 billion and achieved 26% revenue growth in the past year.

1 of 1

Story summary

Sawyer & Company Inc purchased 57,691 shares of Novo Nordisk A/S for $4.96 million, ranking it 15th in their portfolio.
Novo Nordisk's stock declined after Wegovy and Ozempic were added to Medicare's price negotiation list.
Analysts hold a consensus "Buy" rating for Novo Nordisk, with a price target of $140.20.
The company boasts a market cap of $373.61 billion and achieved 26% revenue growth in the past year.